Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:

NCT ID: NCT03516890 Completed - Clinical trials for Hepatocellular Carcinoma

Management of Spontaneous Ruptured Hepatocellular Carcinoma

Start date: January 1, 2005
Study type: Observational

To investigate the best treatment for hepatocellular carcinoma rupture

NCT ID: NCT03516448 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma

Expanding Phase III Study of Tyroserleutide for Injection

Start date: March 24, 2016
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blinded, placebo-controlled, multi-center Clinical Trial. Patients with no tumor lesions 21 days after resection of hepatocellular carcinoma will be randomized in a 1:1 ratio to 1 of the 2 treatment groups´╝Ü6mg/d Tyroserleutide (injection), or placebo

NCT ID: NCT03515369 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Effect of Babaodan on Tumor Recurrence After Curative Resection of Hepatocellular Carcinoma

Start date: May 2018
Phase: Phase 4
Study type: Interventional

The aim of this study is to evaluate the effect of traditional Chinese medicine Babaodan on tumor recurrence of hepatocellular carcinoma after curative resection, as well as the safety of this treatment

NCT ID: NCT03511703 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients

Start date: May 1, 2018
Phase: Phase 2
Study type: Interventional

This study uses to suppress the growth of tumors, extend the patient's survival time and improve the quality of life as much as possible. Through the treatment, the patient is given the chance to undergo surgical resection, thereby more effectively prolonging the OS. Apatinib is a small-molecule VEGFR tyrosine kinase inhibitor. It mainly treats malignant tumors by inhibiting VEGFR and exerting anti-angiogenic effects. Preclinical studies have shown that its antitumor effect is better than that of the similar drug PTK787. Phase II studies of hepatocellular carcinoma have initially demonstrated the effectiveness and safety of apatinib in the treatment of advanced HCC. TACE embolized tumor artery blood supply to inhibit tumor growth and shrink tumors. Based on the therapeutic potential of apatinib, and TACE in their respective tumors, we designed a prospective exploratory clinical study of this patient with advanced liver cancer.

NCT ID: NCT03511222 Not yet recruiting - Gastric Cancer Clinical Trials

Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors

Start date: July 31, 2018
Phase: Phase 1
Study type: Interventional

The investigators hypothesize that vorolanib in combination with checkpoint inhibitors (pembrolizumab for gastric/gastroesophageal (GE) junction cancers and nivolumab for hepatocellular carcinoma (HCC)) may improve immunotherapy efficacy by overcoming treatment resistance of checkpoint inhibitors in gastrointestinal (GI) cancers.

NCT ID: NCT03507998 Recruiting - Clinical trials for Hepatocellular Carcinoma

Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors

Start date: June 17, 2017
Phase: Phase 1
Study type: Interventional

This is a multi-center, open label, repeat dose, Phase 1 study consisting of a Dose Escalation Phase and a Dose Expansion Phase to evaluate safety, pharmacokinetics, and clinical activity.

NCT ID: NCT03507140 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Microbiota Study in Liver Transplanted Patients

Start date: May 2, 2018
Study type: Observational

Many studies describe the relationship between microbiota alteration and the occurrence of metabolic, alcoholic or inflammatory liver diseases. Nevertheless, the modifications of microbiota during liver transplantation (LT) as well as its implication are poorly studied. Similarly, only the intestinal microbiota is studied in this context, and no data are available on the biliary microbiota, even if it is known that bile microbiota can interfere with hepatobiliary diseases. This study proposes a clinical and biological in-depth follow-up with multiple sampling of liver transplanted patients to study biliary and intestinal microbiota alterations along LT, as well as bile acids metabolism in corresponding fluids. Indeed, in recipient samples as saliva, blood, urine, and feces can be taken before LT, and surgeons can easily perform bile sampling during LT. In donors all samples can be taken during liver removal. This offers the opportunity to have a microbiotic landscape of individuals without liver disease (donor), and patients suffering from a chronic liver disease or a liver cancer before and after transplantation. Also, in Grenoble University hospital, in case of biliary anastomotic incongruence, a biliary stent is placed during LT in 60% of recipients. This stent is removed by endoscopic retrograde cholangiopancreatography (ERCP) within 6 months after LT, offering a second opportunity to obtain bile samples in transplanted patients, after the early post-LT period. Patients who do not require a biliary stent will also be included for the study of secondary objectives, as intestinal microbiota is very poorly characterized in liver transplanted patients too. A portion of the patients without biliary stent, may also develop an anastomotic biliary stricture requiring an ERCP. If this ERCP is realized within the follow-up period of the study, the patient will also be included in the primary objective of the study. These multiple and sequential samples will allow a complete analysis of microbiota changes in LT patients and aim to answer to 3 questions: 1. What are the modifications of intestinal and biliary microbiomes during LT? 2. What is the influence of bile acids' composition on intestinal and biliary microbiota? 3. What are the relationships between microbiome alterations and the emergence of LT complications?

NCT ID: NCT03496051 Available - Clinical trials for Hepatocellular Carcinoma

Single Patient Access (Compassionate Use) for Continued Treatment of RO7070179 for Adult Subjects With Advanced Hepatocellular Carcinoma (HCC)

Start date: n/a
Study type: Expanded Access

This is a single-patient access (also referred to as Compassionate Use) setting for a patient who has been treated and benefited from RO7070179 while participating in a clinical study of RO7070179. The patient will receive the dose of RO7070179 at 6 mg/kg/week by IV infusion. Treatment cycles will be defined as 42 (6 weeks) days.

NCT ID: NCT03493763 Recruiting - Clinical trials for Hepatocellular Carcinoma

Study on Recurrence Monitoring of Hepatocellular Carcinoma With 5-Hydroxymethylcytosine Test

Start date: March 1, 2018
Study type: Observational

In this study, investigators aim to find out how plasma 5hmC level changes in hepatocellular carcinoma patients after liver resection, and determine whether 5hmC can be used as a biomarker for HCC recurrence monitoring.

NCT ID: NCT03490461 Completed - Clinical trials for Hepatocellular Carcinoma

Effects of Statin on Hepatocellular Carcinoma Recurrence After Liver Transplantation

Start date: November 22, 2017
Study type: Observational

This study aims to investigate whether statin therapy can help prevent recurrence of hepatocellular carcinoma (HCC) in transplant recipients who had liver transplantation for HCC. Multiple logistic regression analysis will be performed to evaluate the association between statin therapy and the risk of HCC recurrence after LT.